Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 10/20 | 0.64 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.64 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096845 | 0.86 | CYP1A2 (0.69) | MEN1KMT2AALDH1A1CYP1A2RAB9A | |
| SCHEMBL11655094 | 0.86 | NPSR1 (0.62) | ALDH1A1CYP1A2RAB9AFAAHCYP3A4 | |
| SCHEMBL11654124 | 0.84 | RAB9A (0.71) | MEN1KMT2AALDH1A1CYP1A2RAB9A | |
| SCHEMBL8475408 | 0.84 | RAB9A (0.65) | MEN1KMT2AALDH1A1CYP1A2RAB9A | |
| SCHEMBL20169847 | 0.84 | SMN1; SMN2 (0.65) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL607975 | 0.84 | HDAC3 (0.57) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL8490672 | 0.83 | HPGD (0.64) | PARP1PARP10PARP15PARP14MEN1 | |
| SCHEMBL716889 | 0.83 | MAPK1 (0.62) | MEN1KMT2AALDH1A1CYP1A2RAB9A | |
| SCHEMBL2615685 | 0.83 | CYP1A2 (0.53) | MEN1KMT2AALDH1A1CYP1A2RAB9A | |
| SCHEMBL7309841 | 0.83 | CYP1A2 (0.53) | MEN1KMT2AALDH1A1CYP1A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3412279-B1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210008213-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | THE GENERAL HOSPITAL CORPORATION | 2021-01-14 | — | — | US | disclosed |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-9974859-B2 | Nanostructured gels capable of controlled release of entrapped agents | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-24 | — | — | US | disclosed |
| US-5324648-A | Anticoagulants; antitumor agents | GEORGIA TECH RESEARCH CORPORATION (US) | 1994-06-28 | — | — | US | disclosed |
| US-5089633-A | Protease inhibitors, antiinflammatory agents | GEORGIA TECH RESEARCH CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008213-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENCAPSULATED AGENTS | MMP2, CEL, LIPA | PARP1 2727/4885PARP10 3055/4885PARP15 3887/4885 |
| US-20230346946-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | PARP1 2727/4885PARP10 3055/4885PARP15 3887/4885 |
| US-20130280334-A1 | Nanostructured Gels Capable of Controlled Release of Encapsulated Agents | MMP2, CEL, LIPA | PARP1 2727/4885PARP10 3055/4885PARP15 3887/4885 |
| US-20170000888-A1 | NANOSTRUCTURED GELS CAPABLE OF CONTROLLED RELEASE OF ENTRAPPED AGENTS | MMP2, MMP1, GUSB | PARP1 2651/4885PARP10 3218/4885PARP15 3842/4885 |
| US-10675351-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | PARP1 2727/4885PARP10 3055/4885PARP15 3887/4885 |
| US-11672864-B2 | Nanostructured gels capable of controlled release of encapsulated agents | MMP2, CEL, LIPA | PARP1 2727/4885PARP10 3055/4885PARP15 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.